Galmed Pharmaceuticals Reports Strong Cash Position and Expands Therapeutic Focus
Galmed Pharmaceuticals Ltd. reported a strong cash position of $19.2 million with minimal debt, and announced an expansion of its therapeutic focus beyond liver disease to include oncology and cardiometabolic indications. The company emphasizes its commitment to value creation through scientific innovation and responsible financial management.
Galmed Pharmaceuticals Ltd. announced that it ended the third quarter of 2025 with approximately $19.2 million in cash and reported having practically zero debt on its balance sheet. The company highlighted the expansion of its therapeutic focus beyond liver disease, citing new data that supports broader clinical development for Aramchol in oncology and cardiometabolic indications. Galmed stated that it remains financially strong and is committed to both short- and long-term value creation through scientific innovation and responsible financial management. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN34583) on December 01, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
